From Surf Wiki (app.surf) — the open knowledge base
Artivion
| Field | Value |
|---|---|
| name | Artivion, Inc. |
| logo | Artivion Logo TM.png |
| type | Public |
| traded_as | |
| S&P 600 component | |
| foundation | 1984 |
| founder | Steven Anderson |
| Robert McNally | |
| location | Kennesaw, Georgia, United States |
| key_people | J. Patrick Mackin, Chairman of the Board, President & CEO |
| num_employees | 1300 (2022) |
| industry | Medical devices |
| revenue | $298,836,000 (2022) |
| products | Human tissues for transplant, surgical sealants, mechanical heart valves, stents and grafts |
| homepage |
S&P 600 component Robert McNally
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.
History
Artivion was founded as CryoLife in Sarasota, Florida in 1984 by Steven Anderson and Robert McNally. The company later moved from Sarasota to the Atlanta metropolitan area.
In 2000, CryoLife began offering a surgical adhesive called BioGlue used for sealing surgical lacerations under high pressure, such as in arteries.
In February 2008, the FDA gave CryoLife approval for a new kind of heart valve, made from human tissues, which was the first to remove cells from the transplant tissue as opposed to only cleaning the tissue. In giving the approval, the FDA said the new valve, called the CryoValve SynerGraft Pulmonary Valve, had less of a chance of rejection than previous valves.
In 2010, CryoLife acquired the rights to manufacture and distribute PerClot, an absorbable hemostatic powder used in surgery.
In January 2016, the company acquired On-X Life Technologies and its principal product, a mechanical heart valve called the On-X aortic valve replacement, for $130 million.
In October 2017, Artivion acquired JOTEC GmbH, a German-based developer of medical devices for aortic and peripheral vascular diseases, for €225 million. In September 2020, the company acquired Ascyrus Medical.
In 2021, the company received FDA premarket application approval of its PerClot absorbable hemostatic system, which comprised PerClot granules and a delivery system for surgical use. Baxter International agreed to buy PerClot from Artivion in 2021. In 2023, after final FDA approval of the product, the purchase was completed.
References
References
- (12 September 1987). "Tissue frozen for transplant later". Atlanta Journal-Constitution.
- (10 April 2015). "Steven Anderson retires". Atlanta Business Chronicle.
- (14 July 2014). "Leader of Medtronic’s biggest business unit leaves for CEO job". Minneapolis/St. Paul Business Journal.
- "2022 Medtech Big 100". Medical Design and Outsourcing.
- "Archives".
- (6 July 2009). "CryoLife's near-death experience". CNN Money.
- (7 February 2008). "New heart valve may lower risk of rejection". NBC News.
- "Archives".
- (21 January 2016). "CryoLife closes $130m On-X Technologies buyout". MassDevice.
- (13 October 2017). "Jotec gehört jetzt zu US-Unternehmen". Schwarzwalder Bote.
- (3 September 2020). "CryoLife acquires Ascyrus Medical to expand presence in aortic market". Medical Device Network.
- (23 May 2023). "A quick two step: Artivion granted PMA for Perclot, transfers it to Baxter for $18.75M". BioWorld.
- "PerClot Polysaccharide Hemostatic System - P210036".
- (23 May 2023). "A quick two step: Artivion granted PMA for Perclot, transfers it to Baxter for $18.75M u I". BioWorld.
- (30 July 2021). "Baxter acquires PerClot assets from CryoLife". Medical Device Network.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Artivion — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report